Therefore, considering the keys role of NLRP3 inflammasome and the apoptosis pathway in oral cancer pathogenesis, the aim of this study was to investigate the potential effect of BAY 11-7082, an NLRP3 inflammasome inhibitor, on reducing oral cancer growth in an in vitro and in vivo xenograft model of OSCC. Here, NLRP3 is linked to lip and oral cavity carcinoma.